Bisphosphonates in the treatment of osteoporosis: A review of their contribution and controversies

Skeletal Radiology

Volumn 40, Issue 9, 2011, Pages 1191-1196

  Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Alendronate; Ibandronate; Risedronate; Zoledronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; VITAMIN D; ZOLEDRONIC ACID;

DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS CANCER; FEMUR SUBTROCHANTERIC FRACTURE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INTOLERANCE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; JAW OSTEONECROSIS; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY;

ATRIAL FIBRILLATION; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ESOPHAGEAL NEOPLASMS; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; TREATMENT OUTCOME;

EID: 80052043406     PISSN: 03642348     EISSN: 14322161     Source Type: Journal    
DOI: 10.1007/s00256-011-1164-9     Document Type: Review

References (50)

1. H Fleisch RG Russell MD Francis 1969 Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo Science 165 1262 1264 5803538 10.1126/science.165.3899.1262 1:CAS:528:DyaF1MXltVShtL0%3D
2. H Fleisch RG Russell B Simpson RC Muhlbauer 1969 Prevention by a diphosphonate of immobilization "osteoporosis" in rats Nature 223 211 212 5791741 10.1038/223211a0 1:CAS:528:DyaF1MXks12jtLk%3D
3. RD Altman CC Johnston MR Khairi H Wellman AN Serafini RR Sankey 1973 Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans) N Engl J Med 289 1379 1384 4201876 10.1056/NEJM197312272892601 1:STN:280:DyaE2c%2Fjt1yksw%3D%3D
4. R Smith RGG Russell MC Bishop CG Woods M Bishop 1973 Paget's disease of bone: experience with a diphosphonate (disodium etidronate) in treatment Q J Med 42 235 256 4206518 1:STN:280:DyaE2c7jtVemsw%3D%3D
5. WB Frijlink J te Velde OLM Bijvoet G Heynen 1979 Treatment of Paget's disease with (3-amino-1-hydoxypropylidene)-1,1-bisphosphonate (APD) Lancet i 799 803 10.1016/S0140-6736(79)91318-7 (Pubitemid 9150534)
6. FJM Van Breukelen O Bijvoet AT Van Oosterom 1979 Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (A.P.D.) Lancet 313 803 805 10.1016/S0140-6736(79)91319-9 (Pubitemid 9150535)
7. R Valkema F-JFE Vismans SE Papapoulos EKJ Pauwels OLM Bijvoet 1989 Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD Bone Miner 5 183 192 2920240 10.1016/0169-6009(89)90095-0 1:STN:280:DyaL1M7ltVKisA%3D%3D (Pubitemid 19027441)
8. IR Reid AR King CJ Alexander HK Ibbertson 1988 Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1- bisphosphonate (APD) Lancet 1 8578 143 146 2892989 10.1016/S0140-6736(88)92721-3 1:STN:280:DyaL1c7itVKksQ%3D%3D (Pubitemid 18027995)
9. IR Reid SW Heap AR King HK Ibbertson 1988 Two-year follow-up of bisphosphonate (APD) treatment in steroid osteoporosis Lancet 2 8620 1144 2903360 10.1016/S0140-6736(88)90566-1 1:STN:280:DyaL1M%2FjvVygtA%3D%3D
10. JE Rossouw GL Anderson RL Prentice, et al. 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 321 333 12117397 10.1001/jama.288.3.321 1:CAS:528:DC%2BD38Xltlegs7k%3D (Pubitemid 34761611)
11. A Grey M Bolland D Wattie, et al. 2010 Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial J Bone Miner Res 25 2251 2255 20499349 10.1002/jbmr.103 1:CAS:528:DC%2BC3cXhtlaktbrO
12. MJ Bolland AB Grey AM Horne SE Briggs MG Thomas RB Ellis-Pegler, et al. 2008 Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months J Bone Miner Res 23 1304 1308 18627266 10.1359/jbmr.080312 1:CAS:528:DC%2BD1cXpvFyiu7c%3D (Pubitemid 352040185)
13. GH Nancollas R Tang RJ Phipps Z Henneman S Gulde W Wu, et al. 2006 Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite Bone 38 617 627 16046206 10.1016/j.bone.2005.05.003 1:CAS:528:DC%2BD28XjvFSjtr4%3D
14. JE Dunford K Thompson FP Coxon SP Luckman FM Hahn CD Poulter, et al. 2001 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates J Pharmacol Exp Ther 296 235 242 11160603 1:CAS:528:DC%2BD3MXoslaluw%3D%3D (Pubitemid 32112446)
15. C Christiansen LB Tanko L Warming A Moelgaard S Christgau P Qvist, et al. 2003 Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate Osteoporos Int 14 609 613 12830369 10.1007/s00198-003-1409-0 1:CAS:528:DC%2BD3sXls1ynsLw%3D (Pubitemid 36975561)
16. NB Watts A Chines WP Olszynski CD McKeever MR McClung X Zhou, et al. 2008 Fracture risk remains reduced one year after discontinuation of risedronate Osteoporos Int 19 365 372 17938986 10.1007/s00198-007-0460-7 1:CAS:528:DC%2BD1cXhtlOqsb4%3D (Pubitemid 351199181)
17. DD Mellstrom OH Sorensen S Goemaere C Roux TD Johnson AA Chines 2004 Seven years of treatment with risedronate in women with postmenopausal osteoporosis Calcif Tissue Int 75 462 468 15455188 10.1007/s00223-004-0286-7 1:STN:280:DC%2BD2M%2FisFSktA%3D%3D (Pubitemid 40174503)
18. DM Black AV Schwartz KE Ensrud, et al. 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial long-term Extension (FLEX): a randomized trial JAMA 296 2927 2938 17190893 10.1001/jama.296.24.2927 1:CAS:528:DC%2BD2sXnvVGh (Pubitemid 46021497)
19. DM Black PD Delmas R Eastell, et al. 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 17476007 10.1056/NEJMoa067312 1:CAS:528:DC%2BD2sXltVSktLc%3D (Pubitemid 46698462)
20. R Marcus M Wong H Heath JL Stock 2002 Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint Endocr Rev 23 16 37 11844743 10.1210/er.23.1.16 1:CAS:528:DC%2BD38XitFOqu7k%3D (Pubitemid 34185305)
21. MR McClung P Geusens PD Miller, et al. 2001 Effect of risedronate on the risk of hip fracture in elderly women N Engl J Med 344 333 340 11172164 10.1056/NEJM200102013440503 1:CAS:528:DC%2BD3MXht1Wlu7g%3D (Pubitemid 32107641)
22. DM Black SR Cummings DB Karpf, et al. 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1535 1541 8950879 10.1016/S0140-6736(96)07088-2 1:CAS:528: DyaK2sXisFCktQ%3D%3D (Pubitemid 26411651)
23. KW Lyles CS Colon-Emeric JS Magaziner, et al. 2007 Zoledronic acid and clinical fractures and mortality after hip fracture N Engl J Med 357 1799 1809 17878149 10.1056/NEJMoa074941 1:CAS:528:DC%2BD2sXht1Kit7nN (Pubitemid 350044800)
24. MJ Bolland AB Grey GD Gamble IR Reid 2010 Effect of osteoporosis treatment on mortality: A meta-analysis J Clin Endocrinol Metab 95 1174 1181 20080842 10.1210/jc.2009-0852 1:CAS:528:DC%2BC3cXjs1Kqtrg%3D
25. Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab. 2011; doi: jc.2010-2730v1-jc.2010-2730.
26. IR Reid GD Gamble P Mesenbrink P Lakatos DM Black 2010 Characterization of and risk factors for the acute-phase response after zoledronic acid J Clin Endocrinol Metab 95 4380 4387 20554708 10.1210/jc.2010-0597 1:CAS:528: DC%2BC3cXht1Wms73F
27. IR Reid 2009 Osteonecrosis of the jaw-who gets it, and why? Bone 44 4 10 18948230 10.1016/j.bone.2008.09.012 1:CAS:528:DC%2BD1cXhsFahtLnK
28. Stopeck AT, Lipton A, Body JJ, Steger GG TK, de Boer RH, Lichinitser M, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;(in press)
29. VM Cartsos S Zhu AI Zavras 2008 Bisphosphonate use and the risk of adverse jaw outcomes J Am Dent Assoc 139 23 30 18167381
30. M Pazianas WA Blumentals PD Miller 2008 Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker Osteoporos Int 19 773 779 17999023 10.1007/s00198-007-0502-1 1:CAS:528:DC%2BD1cXltFyjtbo%3D
31. EBK Kwek SK Goh JSB Koh MA Png TS Howe 2008 An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy? Injury 39 224 231 18222447 10.1016/j.injury.2007.08.036
32. BA Lenart DG Lorich JM Lane 2008 Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate N Engl J Med 358 1304 1306 18354114 10.1056/NEJMc0707493 1:CAS:528:DC%2BD1cXjvVarsb8%3D (Pubitemid 351439247)
33. Feldman F. Atypical diaphyseal femoral fractures-new aspects. Skeletal Radiol. 2011;(in press)
34. DM Black MP Kelly HK Genant, et al. 2010 Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur N Engl J Med 362 1761 1771 20335571 10.1056/NEJMoa1001086 1:CAS:528:DC%2BC3cXmtVSrsr4%3D
35. JW Nieves JP Bilezikian JM Lane TA Einhorn Y Wang M Steinbuch, et al. 2010 Fragility fractures of the hip and femur: incidence and patient characteristics Osteoporos Int 21 399 408 19484169 10.1007/s00198-009-0962-6 1:STN:280:DC%2BC3c%2FovFCktQ%3D%3D
36. LY Park-Wyllie MM Mamdani DN Juurlink GA Hawker N Gunraj PC Austin, et al. 2011 Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women JAMA 305 783 789 21343577 10.1001/jama.2011.190 1:CAS:528:DC%2BC3MXis1ymurw%3D
37. B Abrahamsen P Eiken R Eastell 2009 Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study J Bone Miner Res 24 1095 1102 19113931 10.1359/jbmr.081247 1:CAS:528:DC%2BD1MXmvFyjtrY%3D
38. B Abrahamsen P Eiken R Eastell 2010 Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis J Clin Endocrinol Metab 95 5258 5265 20843943 10.1210/jc.2010-1571 1:CAS:528:DC%2BC3cXhs1arsLvI
39. R Karam J Camm M McClung 2007 Yearly zoledronic acid in postmenopausal osteoporosis N Engl J Med 357 712 713 17703529 1:CAS:528:DC%2BD2sXptFKqtrY%3D (Pubitemid 47267247)
40. SR Cummings AV Schwartz DM Black 2007 Alendronate and atrial fibrillation N Engl J Med 356 1895 1896 17476024 10.1056/NEJMc076132 1:CAS:528: DC%2BD2sXltVaisb0%3D (Pubitemid 46698498)
41. EM Lewiecki C Cooper E Thompson F Hartl D Mehta SE Papapoulos 2010 Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials Int J Clin Pract 64 821 826 20337751 10.1111/j.1742-1241.2010. 02335.x 1:CAS:528:DC%2BC3cXnt1KjsL0%3D
42. HT Sorensen S Christensen F Mehnert L Pedersen RD Chapurlat SR Cummings, et al. 2008 Use of bisphosphonates among women and risk of atrial-fibrillation and flutter: population based case-control study BMJ 336 813 816 18334527 10.1136/bmj.39507.551644.BE (Pubitemid 351548223)
43. Abrahamsen B, Eiken P, Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med. 2009;265(5):581-92.
44. TJ Bunch JL Anderson HT May JB Muhlestein BD Home BG Crandall, et al. 2009 Relation of bisphosphonate therapies and risk of developing atrial fibrillation Am J Cardiol 103 824 828 19268739 10.1016/j.amjcard.2008.11.037 1:CAS:528:DC%2BD1MXisl2rtrY%3D
45. DK Wysowski 2009 Reports of esophageal cancer with oral bisphosphonate use N Engl J Med 360 89 90 19118315 10.1056/NEJMc0808738 1:CAS:528: DC%2BD1MXitVShug%3D%3D
46. B Abrahamsen P Eiken R Eastell 2009 More on reports of esophageal cancer with oral bisphosphonate use N Engl J Med 360 1789 1789 19387022 10.1056/NEJMc096026 1:CAS:528:DC%2BD1MXkvVygtbw%3D
47. DH Solomon A Patrick MA Brookhart 2009 More on reports of esophageal cancer with oral bisphosphonate use N Engl J Med 360 1789 1790 19391255 10.1056/NEJMc096026 1:CAS:528:DC%2BD1MXkvVymu7w%3D
48. J Green G Czanner G Reeves J Watson L Wise V Beral 2010 Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort BMJ 341 c4444 20813820 10.1136/bmj.c4444
49. CR Cardwell CC Abnet MM Cantwell LJ Murray 2010 Exposure to oral bisphosphonates and risk of esophageal cancer JAMA 304 657 663 20699457 10.1001/jama.2010.1098 1:CAS:528:DC%2BC3cXhtVelsbbO
50. RR Recker PD Delmas J Halse, et al. 2008 Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure J Bone Miner Res 23 6 16 17892374 10.1359/jbmr.070906 1:CAS:528:DC%2BD1cXhtVCmt7c%3D